Other
Endometrial Hyperplasia Without Atypia
5
Pipeline Programs↗
1
Active Trials↗
4
Companies Involved↗
Endometrial Hyperplasia without Atypia is an early-stage landscape with 5 programs across 4 companies. The most active players are EMD Serono, Solvay Pharmaceuticals, Eli Lilly. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 1
No programs
Phase 2
No programs
Approved
No programs
Analysis
Trial Status
3
clinical trials
Unknown status1 · 33%
Completed1 · 33%
Not yet recruiting1 · 33%
Clinical Trials
Trial Activity
Longitudinal Follow-up in Women With Endometrial Hyperplasia Without Atypia
Unknown status·—·Phase 3·NCT05292573·1,000 enrolled
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
Completed·—·Phase 3·NCT03675139·471 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)